Sino Biopharmaceutical
Update in progress1177.HK (HKSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Sino Biopharmaceutical Limited is an investment holding company that operates as an R&D pharmaceutical conglomerate in China. It runs three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The group develops and markets oncology, liver disease, respiratory, and surgery/analgesia medicines under multiple brands, and pursues long‑term investments and healthcare ventures. Established 2000, it is headquartered in Wan Chai, Hong Kong.
Company score
- Sentiment
- 0.38
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.14
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketHKSE (HKG)
- LocationHong Kong
- CEOMr. S. Y. Tse
- Founded2000
- Employees22,838
- Websitewww.sbpgroup.com
Identifiers
- ISINKYG8167W1380
- FIGIBBG000C6XDL4